Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)

PaperCitations, authors & open-access status

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803) is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 241 citations, 2012 year and bronze oa status.